Menu
Back to User profile » Prof. Dr. Seung Hyeun Lee
Papers published by Prof. Dr. Seung Hyeun Lee:
Capmatinib in MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma with Extensive Central Nervous System Metastasis
Kim TW, Lee KM, Lee SH
OncoTargets and Therapy 2022, 15:941-946
Published Date: 31 August 2022
Serum Reactive Oxygen Species Modulator 1 as a Novel Predictive Biomarker for Resected Lung Adenocarcinoma: A Retrospective Pilot Study
Chang B, Hwang IK, Lee SH
OncoTargets and Therapy 2021, 14:5097-5106
Published Date: 21 October 2021
Primary Resistance to Immune Checkpoint Blockade in an STK11/TP53/KRAS-Mutant Lung Adenocarcinoma with High PD-L1 Expression
Kwack WG, Shin SY, Lee SH
OncoTargets and Therapy 2020, 13:8901-8905
Published Date: 7 September 2020
High PD-L1 Expression is Associated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy
Yoon BW, Chang B, Lee SH
OncoTargets and Therapy 2020, 13:8273-8285
Published Date: 20 August 2020
Diagnostic and Predictive Values of 18F-FDG PET/CT Metabolic Parameters in EGFR-Mutated Advanced Lung Adenocarcinoma
Hong IK, Lee JM, Hwang IK, Paik SS, Kim C, Lee SH
Cancer Management and Research 2020, 12:6453-6465
Published Date: 28 July 2020
Reactive Oxygen Species Modulator 1 As An Adverse Prognostic Marker In Stage III Non-Small Cell Lung Cancer Treated With Radiotherapy: A Retrospective Pilot Study
Kong M, Sung JY, Lee SH
OncoTargets and Therapy 2019, 12:8263-8273
Published Date: 9 October 2019
Clinical utility of a novel natural killer cell activity assay for diagnosing non-small cell lung cancer: a prospective pilot study
Choi SI, Lee SH, Park JY, Kim KA, Lee EJ, Lee SY, In KH
OncoTargets and Therapy 2019, 12:1661-1669
Published Date: 27 February 2019
NANOG as an adverse predictive marker in advanced non–small cell lung cancer treated with platinum-based chemotherapy
Chang B, Park MJ, Choi SI, In KH, Kim CH, Lee SH
OncoTargets and Therapy 2017, 10:4625-4633
Published Date: 19 September 2017